505 related articles for article (PubMed ID: 18852012)
1. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
2. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
3. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2009 Dec; 22(12):1962-74. PubMed ID: 19842618
[TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.
Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE
Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512
[TBL] [Abstract][Full Text] [Related]
5. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E; Abuhammad A; Ryan A
Br J Pharmacol; 2014 Jun; 171(11):2705-25. PubMed ID: 24467436
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T; Boukouvala S; Agianian B; Fakis G
Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
8. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.
Goodfellow GH; Dupret JM; Grant DM
Biochem J; 2000 May; 348 Pt 1(Pt 1):159-66. PubMed ID: 10794727
[TBL] [Abstract][Full Text] [Related]
9. Arylamine N-acetyltransferases: from structure to function.
Sim E; Walters K; Boukouvala S
Drug Metab Rev; 2008; 40(3):479-510. PubMed ID: 18642144
[TBL] [Abstract][Full Text] [Related]
10. Effect of arylamine acetyltransferase Nat3 gene knockout on N-acetylation in the mouse.
Sugamori KS; Brenneman D; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Drug Metab Dispos; 2007 Jul; 35(7):1064-70. PubMed ID: 17403913
[TBL] [Abstract][Full Text] [Related]
11. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens.
Fretland AJ; Doll MA; Gray K; Feng Y; Hein DW
Toxicol Appl Pharmacol; 1997 Feb; 142(2):360-6. PubMed ID: 9070359
[TBL] [Abstract][Full Text] [Related]
12. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts.
Boukouvala S; Sim E
Basic Clin Pharmacol Toxicol; 2005 May; 96(5):343-51. PubMed ID: 15853926
[TBL] [Abstract][Full Text] [Related]
13. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
[TBL] [Abstract][Full Text] [Related]
14. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
15. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
16. Description of a novel polymorphic gene encoding for arylamine N-acetyltransferase in the rhesus macaque (Macaca mulatta), a model animal for endometriosis.
Fakis G; Boukouvala S; Kawamura A; Kennedy S
Pharmacogenet Genomics; 2007 Mar; 17(3):181-8. PubMed ID: 17460546
[TBL] [Abstract][Full Text] [Related]
17. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies.
Wang H; Vath GM; Gleason KJ; Hanna PE; Wagner CR
Biochemistry; 2004 Jun; 43(25):8234-46. PubMed ID: 15209520
[TBL] [Abstract][Full Text] [Related]
18. Arylamine N-acetyltransferases. Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes.
Wagner CR; Bergstrom CP; Koning KR; Hanna PE
Drug Metab Dispos; 1996 Feb; 24(2):245-53. PubMed ID: 8742238
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.
Walker K; Ginsberg G; Hattis D; Johns DO; Guyton KZ; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):440-72. PubMed ID: 20183529
[TBL] [Abstract][Full Text] [Related]
20. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening.
Kawamura A; Graham J; Mushtaq A; Tsiftsoglou SA; Vath GM; Hanna PE; Wagner CR; Sim E
Biochem Pharmacol; 2005 Jan; 69(2):347-59. PubMed ID: 15627487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
